EFFICACY OF ORALLY-ADMINISTERED ONDANSETRON IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING - A DOSE RANGING STUDY

被引:59
作者
KENNY, GNC
OATES, JDL
LEESER, J
ROWBOTHAM, DJ
LIP, H
RUST, M
SAUR, P
ONSRUD, M
HAIGH, CG
机构
[1] ROYAL LIVERPOOL UNIV HOSP,DEPT ANAESTHESIA,LIVERPOOL L7 8XP,ENGLAND
[2] ONZE LIEVE VROUW HOSP,DEPT ANAESTHESIA,1091 HA AMSTERDAM,NETHERLANDS
[3] UNIV LEICESTER,LEISTER ROYAL INFIRM,DEPT ANAESTHESIA,LEISTER LE1 5WW,ENGLAND
[4] SOPHIA HOSP,DEPT ANAESTHESIA,8000 GK ZWOLLE,NETHERLANDS
[5] TECH UNIV MUNICH,INST ANAESTHESIOL,W-8000 MUNICH 80,GERMANY
[6] UNIV GOTTINGEN,ANAESTHESIOL KLIN,W-3400 GOTTINGEN,GERMANY
[7] UNIV HOSP TRONDHEIM,DEPT GYNAECOL,N-7006 TRONDHEIM,NORWAY
[8] GLAXO GRP RES LTD,DEPT GASTROINTESTINAL NEW CHEM ENTITIES,GREENFORD UB6 0HE,MIDDX,ENGLAND
关键词
ANTAGONISTS; 5-HYDROXYTRYPTAMINE; ONDANSETRON; SURGERY; GYNECOLOGICAL; VOMITING; POSTOPERATIVE;
D O I
10.1093/bja/68.5.466
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
In a placebo-controlled, double-blind study, we have compared the efficacy of ondansetron 16 mg, 8 mg and 1 mg administered 8-hourly for prevention of postoperative nausea and vomiting. We studied 995 patients undergoing major gynaecological surgery; 982 were included in the analysis. Study medication was administered 1 h before induction of anaesthesia and second and third doses were given 8 and 16 h after the first. The treatment groups were similar for patient characteristics, surgical procedures, anaesthetics administered and opioids given. The frequency of nausea was 75%, 70%, 56% and 55% after placebo and ondansetron 1 mg, 8 mg and 16 mg, respectively; the corresponding frequencies of vomiting were 60%, 55%, 37% and 37%. Ondansetron 8 mg was as effective as 16 mg and both resulted in significant reductions in nausea and vomiting compared with placebo and ondansetron 1 mg (P < 0.001).
引用
收藏
页码:466 / 470
页数:5
相关论文
共 8 条
  • [1] PHARMACOLOGICAL PROPERTIES OF GR38032F, A NOVEL ANTAGONIST AT 5-HT3 RECEPTORS
    BUTLER, A
    HILL, JM
    IRELAND, SJ
    JORDAN, CC
    TYERS, MB
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1988, 94 (02) : 397 - 412
  • [2] CHAFFEE BJ, 1991, CLIN PHARMACY, V10, P430
  • [3] PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST
    CUNNINGHAM, D
    POPLE, A
    FORD, HT
    HAWTHORN, J
    GAZET, JC
    CHALLONER, T
    COOMBES, RC
    [J]. LANCET, 1987, 1 (8548) : 1461 - 1463
  • [4] ONDANSETRON - A SEROTONIN RECEPTOR (5-HT3) ANTAGONIST FOR ANTINEOPLASTIC CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
    KOHLER, DR
    GOLDSPIEL, BR
    [J]. DICP-THE ANNALS OF PHARMACOTHERAPY, 1991, 25 (04): : 367 - 380
  • [5] LEESER J, 1991, ANESTH ANALG, V72, P751
  • [6] COMPARISON OF THE USE OF DOMPERIDONE, DROPERIDOL AND METOCLOPRAMIDE IN THE PREVENTION OF NAUSEA AND VOMITING FOLLOWING MAJOR GYNECOLOGICAL SURGERY
    MADEJ, TH
    SIMPSON, KH
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 1986, 58 (08) : 884 - 887
  • [7] ANESTHESIA AND EMESIS .1. ETIOLOGY
    PALAZZO, MGA
    STRUNIN, L
    [J]. CANADIAN ANAESTHETISTS SOCIETY JOURNAL, 1984, 31 (02) : 178 - 187
  • [8] PRIESTMAN TJ, 1989, EUR J CANCER CLIN ON, V25, pS29